The main purpose of GEN-PEAK is to characterise the movement of the drug RG6042 into, through, and out of the cerebrospinal fluid and plasma in addition to reaction to the drug. The study will also look at the time course and recovery profile of cerebrospinal fluid, mutant huntingtin lowering in response to RG6042 treatment after intrathecal administration of RG6042 to patients with manifest Huntington’s disease.
Estimated Study Completion Date: 24 December, 2021